Extreme thrombocytosis defined by a platelet count of ≥ 1000*109/L was not associated with bleeding or acquired vWF syndrome. vWF profiling and JAK2V617F VAF contribute to thrombosis and bleeding risk assessment in patients with MPNs and should be incorporated routinely at diagnosis and during follow-up. The gene discussed is VWF; the disease is Thrombocytosis.